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Abstract
Introduction: The non-histone nuclear protein high mobility group box protein-1 (HMGB1) is typically associated
with nucleosomes, but may shuttle between the nucleus and the cytoplasm, and under some conditions also be
released extracellularly and participate in systemic inflammation. Monoclonal HMGB1-targeting antibodies can
ameliorate murine polyarthritis and lupus-like disease. Interestingly, autoantibodies against HMGB1 have also been
described in patients with systemic lupus erythematosus (SLE), but their clinical implications remain elusive. The
main aims of this study were to detect serum anti-HMGB1 antibodies in patients with SLE and relate them to other
types of antinuclear antibodies (ANA), and to disease activity.
Methods: 188 Swedish SLE patients meeting the 1982 American College of Rheumatology classification criteria
and/or the 2012 Systemic Lupus International Collaborating Clinics classification criteria participated in the study.
Anti-HMGB1 antibody levels were analysed in patient and control (n = 112) sera by an in-house ELISA using
recombinant histidine-tagged HMGB1. SLE sera were also analysed for ANA by immunofluorescence (IF) microscopy
(IF-ANA) using fixed HEp-2 cells, and by a line-blot assay for antigen fine-specificities. To quantify antibodies to
double-stranded DNA, a fluoroenzyme-immunoassay was employed.
Results: At inclusion, 23 % of the SLE patients were anti-HMGB1 antibody positive compared to 5 % of the controls.
Anti-HMGB1 antibodies occurred in 49 % of the IF-ANA positive SLE patients, and in 34 % of IF-ANA negative cases
(p = 0.004). Levels of anti-HMGB1 antibodies correlated with anti-dsDNA antibody levels (r = 0.49; p < 0.001). Significant,
but less pronounced correlations were found regarding anti-HMGB1 and SLE disease activity index (SLEDAI-2K: r = 0.15;
p = 0.04), classical complement function (r = -0.24; p = 0.002) and complement protein C4 (r = -0.23; p = 0.002). Average
anti-HMGB1 antibody levels were significantly higher among patients with homogenous ± other IF-ANA staining
patterns (median 180 AU) compared to IF-ANA negative cases (median 83 AU) (p = 0.004). Rabbit anti-HMGB1
antibodies gave rise to cytoplasmic, but not nuclear, staining of HEp-2 cells.
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Conclusions: We confirm that anti-HMGB1 antibodies are common in SLE and correlate with disease activity variables.
Although anti-HMGB1 antibodies measured by ELISA often coincide with nuclear IF-ANA staining, our results indicate
that anti-HMGB1 antibodies do not give rise to nuclear staining of the predominantly used commercial HEp-2 cell slides.
Keywords: HMGB1, Autoantibodies, SLE, Antinuclear antibodies, Inflammation, Clinical phenotype, Complement proteins
Introduction
Abnormally high serum levels of antinuclear antibodies
(ANA) assessed by indirect immunofluorescence (IF)
microscopy (IF-ANA) is one of the 11 classification cri-
teria for systemic lupus erythematosus (SLE) according
to the American College of Rheumatology (ACR) 1982
and the suggested update 1997 [1, 2]. Applying a cut-off
level >95th percentile among healthy female blood
donors, IF-ANA occurs in the large majority (98–99 %)
of SLE patients at diagnosis [3], although the point
prevalence among established cases is considerably lower
[4–6]. Depending on the many different nuclear target
antigens for ANA, different IF-staining patterns can be
seen. Thus, antibodies against double-stranded (ds)
DNA, histones and DNA-histone complexes typically
produce a homogeneous nuclear staining pattern on
non-dividing cells, and staining of the condensed
chromatin-associated antigens in mitotic cells. In con-
trast, ANA specific for extrachromosomal antigens
can be identified as a speckled nuclear staining pattern in
non-dividing cells, and diffuse extra-chromosomal
staining of dividing cells. In addition, other IF-ANA
staining patterns can be distinguished on HEp-2 cells
(e.g., centromeric and nucleolar patterns) and indi-
cate other antigen specificities and clinical character-
istics [7, 8].
Increased apoptosis and impaired clearance of apop-
totic material results in raised levels of circulating
autoantigens and increased exposure of these antigens
to the adaptive immune system. This may underlie the ex-
cessive production of ANA in SLE, and the formation of
circulating and tissue-bound immune complexes (ICs),
which probably contribute to SLE pathogenesis [9–11].
Thus, uncontrolled autoimmune responses, abnormal for-
mation of autoantibodies/ICs, and increased extrahepatic
IC deposition may promote inflammation and result in a
large variety of clinical manifestations ranging from skin
rash and arthritis to cytopenia, nephritis, and neurological
symptoms [3].
High mobility group box-1 protein (HMGB1) was
originally discovered as a 25 kDa DNA-binding protein
that participates in many nuclear functions, e.g., regulation
of gene transcription, chromatin replication and DNA
repair [12]. Triggered by trauma, infection and other
pro-inflammatory stimuli, HMGB1 can also be released
extracellularly and act as a pro-inflammatory mediator,
e.g., inducing monocyte synthesis of pro-inflammatory cy-
tokines and chemokines [13–16]. The pro-inflammatory
functions of HMGB1 are determined by the configura-
tions of the oxidative states on the three cysteine residues,
C23, C45 and C106 [17]. HMGB1 can also instantly leak
extracellularly from dying cells due to ruptured plasma
membranes [18]. During silent apoptotic cell death,
HMGB1 is normally not released, provided that the
apoptotic material is properly engulfed and degraded
by phagocytic cells. However, due to the insufficient
clearance of apoptotic debris in SLE, secondary necrosis
will occur and significant amounts of DNA-attached
HMGB1 will be released [19]. Such DNA-bound HMGB1
is not cytokine-inducing due to irreversible oxidation of
the critical cysteine at position 106 that is essential for
HMGB1-mediated cytokine induction [20]. However,
HMGB1 attached to DNA or by itself is highly im-
munogenic as a nuclear autoantigen irrespective of its
redox state, and stimulates the production of auto-
antibodies [21, 22].
In SLE, HMGB1 has been shown to potentiate the
production of ANA recognising nucleosomes and
dsDNA [21, 22]. HMGB1 bound to DNA-containing ICs
has also been shown to induce interferon-alpha (IFN-α)
production by plasmacytoid dendritic cells, and to acti-
vate autoreactive B cells [23]. Serum levels of HMGB1
are elevated in SLE patients and have been found to
correlate positively with disease activity [24–27], and
inversely with levels of complement proteins C3 and C4
[26, 28]. HMGB1 may also serve as an autoantigen,
leading to the production of anti-HMGB1 antibodies
[26, 29–32]. Anti-HMGB1/HMGB2 antibodies were first
described as a type of “perinuclear” anti-neutrophil
cytoplasm antibody (ANCA) in ulcerative colitis [29].
Circulating anti-HMGB1 antibodies have also been
reported in SLE [26, 30–32] where the antibody levels
appear to correlate with the SLE disease activity index
(SLEDAI) and coincide with renal involvement [26].
However, the possible biological/clinical importance of
anti-HMGB1 antibodies remains to be clarified.
The present study was undertaken to further elucidate
the occurrence, and clinical and serological correlates of
anti-HMGB1 antibodies in patients with SLE. Due to the
typical nuclear localization of HMGB1, anti-HMGB1
antibodies were furthermore evaluated as a potential
source of IF-ANA.
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Methods
Patients and control subjects
Patients diagnosed with SLE (n = 188; 167 women, 21
men; mean age 49.1 years; age range 18–88 years) were
included in the study. All patients took part in the pro-
spective, structured follow-up program “KLURING”
(Swedish acronym for Clinical LUpus Register In
Northeastern Gothia) [7, 33, 34] at the rheumatology out-
patient clinic, Linköping University Hospital, Sweden. Of
the 188 patients, 163 (87 %) met at least 4 of the 1982
American College of Rheumatology classification criteria
(ACR-82). Another 25 patients (13 %) solely fulfilled the
2012 Systemic Lupus International Collaborating Clinics
(SLICC) classification criteria [35], whereas 158 patients
(84 %) met both ACR-82 and SLICC-12 criteria. The pa-
tients were recruited consecutively. Most were prevalent
cases (165 patients, 88 %), but 23 patients (12 %) had
recent-onset disease at the time of sampling. The mean
disease duration was 11 years (range 0–45 years). The SLE
disease activity index 2000 (SLEDAI-2K) was recorded at
each visit [36] and the SLICC/ACR damage index was
registered prospectively after inclusion in KLURING [37].
Further characteristics of the patients are summarized in
Table 1.
Randomly selected age- and sex-matched individuals
from the general population (n = 112; 102 women, 10
men; mean age 47 years; range 19–84 years), none of
whom had a diagnosis of SLE, were recruited from the
Swedish population register, and served as controls for
the anti-HMGB1 antibody analyses.
Peripheral venous blood was drawn from each individual
at baseline. Serum samples were prepared and stored
at −70 °C until analyzed. Eighteen patients, all meeting the
ACR-82 criteria, were selected for consecutive analyses
(2–13 visits per patient), due to fluctuations in disease
activity over time (i.e., SLEDAI-2K peak score of at least 4
points).
Production of recombinant HMGB1
Recombinant rat histidine-tagged HMGB1 cDNA was
cloned into pET28a vector (Clontech, Mountain View, CA,
USA) as previously published [38] and transformed into
BL21 (DE3) strain (Stratagene, Santa Clara, CA, USA). The
protein, with 99 % homology to human HMGB1, was
purified with Ni Sepharose High Performance affinity
media (GE Healthcare, Chalfont St. Giles, UK) according
to the protocol supplied by the manufacturer, followed by
gel filtration on a Superdex 75 column (GE Healthcare)
with phosphate-buffered saline (PBS), pH 7.4, as running
buffer. Endotoxin was removed by addition of 1 % Triton
X-114 and incubation at 4 °C for 30 minutes, followed by
incubation in a 37 °C water bath for 10 minutes, and sub-
sequently centrifugation at 18,300 g/25 °C for 10 minutes.
This procedure was repeated once and yielded endotoxin
levels below 0.003 EU/μg protein, according to the Limulus
amoebocyte lysate assay (analyzed by the clinical laboratory
at Karolinska University Hospital, Stockholm, Sweden).
The protein preparation was also free from DNA as evalu-
ated by agarose gel electrophoresis and staining for DNA
with GelRed (Biotium, Hayward, CA, USA).
Anti-HMGB1 autoantibodies
Autoantibodies against HMGB1 were measured by an in-
house enzyme-linked immunosorbent assay (ELISA).
Briefly, Nunc maxisorp 96-well plates (Thermo Fisher Sci-
entific, Uppsala, Sweden) were coated with recombinant
rat histidine-tagged HMGB1 (10 μg/ml in 50 mM carbon-
ate buffer, pH 9.6) overnight at 4 °C. The well surfaces
were blocked by incubation with 5 % non-fat dry milk
powder (Bio-Rad, Hercules, CA, USA) in PBS for 30 mi-
nutes. Serum samples were diluted 1:500 in PBS/0.05 %
Tween/1 % milk powder and a 7-point standard curve
with pooled positive SLE sera were prepared (starting at
dilution 1:500 (=1600 arbitrary units (AU)) followed by
serial two-fold dilutions). Samples and standards were in-
cubated in the wells for 2 hours at room temperature.
Secondary horseradish peroxidase-conjugated rabbit
anti-human IgG antibody (Dako, Glostrup, Denmark)
was diluted 1:2000 in PBS/0.05 % Tween/1 % milk
powder, added to the plate and incubated at room
temperature for 2 hours. Plates were developed with tetra-
methylbenzidine substrate (Sigma-Aldrich, St. Louis, MO,
USA). The reaction was stopped by adding 2M H2SO4.
AU were calculated by normalization against a standard
pool of IgG anti-HMGB1-positive serum samples from 11
different SLE patients. The cutoff value of 300 AU was
calculated based on the mean value of anti-HMGB1 + two
standard deviations among the 112 referents.
Indirect immunofluorescence microscopy for ANA
patterns and HMGB1 localisation
SLE sera diluted 1:200 were also analyzed for IF-ANA
using multispot slides with fixed HEp-2 cells (Immu-
noConcepts, Sacramento, CA, USA). At this cut-off limit
<5 % of healthy female blood donors test ANA-positive
[4]. The HEp-2 cell slides were incubated with PBS-
diluted sera for 30 minutes, washed with PBS for 10 mi-
nutes, and incubated with fluorescein-isothiocyanate
(FITC)-conjugated γ-chain-specific rabbit polyclonal anti-
human IgG (DAKO). After incubation and washing, the
microscope slides were mounted with Fluorescence
Mounting Medium (DAKO) and cover slips. The micro-
scope prerequisites have been specified previously [4].
Based on the immuno-morphological staining pattern,
samples were categorized into three groups: 1) ANA-
negative, 2) homogenous ANA ± other ANA patterns,
and 3) other ANA patterns: speckled, centromeric,
nucleolar or multiple nuclear dots.
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For immunomorphological localization of HMGB1,
fixed HEp-2 cells (see above), and non-fixed 5-μm cryo-
stat sections of rat liver, respectively, were incubated for
30 minutes with polyclonal rabbit anti-HMGB1 (Abcam,
Cambridge, UK; dilution 1:100 in PBS). After PBS washing,
the slides were incubated for 30 minutes with FITC-
conjugated polyclonal goat anti-rabbit IgG-Fc diluted
1:50 (Abcam).
ANA fine specificity
ANA fine specificities were analyzed using a line blot kit
(ANA Profile 5, EUROIMMUN, Lübeck, Germany). The
assay was run according to the manufacturer’s instructions
on an automated EUROBlotmaster (EUROIMMUN) in-
strument. Briefly, the antigen-coated immunoblot strips
were incubated for 30 minutes with serum samples diluted
1:101 with PBS. After washing, alkaline phosphatase-
labeled anti-human IgG, diluted 1:10, was added and incu-
bated for 30 minutes. After washing, substrate solution
(nitrobluetetrazoliumchlorid/5-bromo-4-chloro-3-indolyl-
phosphate) was added for 10 minutes. All incubations
were performed at room temperature. The enzymatic
reaction was stopped by washing the strips with distilled
water and the blot intensities were automatically semi-
quantified by densitometry with the EUROLineScan
(EUROIMMUN). Cut-off levels for positive tests were set
to a signal intensity of ≥11 arbitrary units according to the
manufacturer’s suggestion. Apart from HMGB1, the three
isolated target antigens of interest in this study were: 1)
histone-1 stripped nucleosomes (Nu2) derived from calf
thymus, 2) a mixture of histone H1 and H2b purified from
calf thymus, and 3) dsDNA (isolated from salmon testes).
Fluoroenzyme-immunoassay for quantification of
anti-dsDNA antibodies
Anti-dsDNA detections were performed using the
Phadia250 instrument (EliA™ dsDNA; Thermo Fisher
Scientific, Uppsala, Sweden) as described elsewhere [39].
Briefly, serum samples were added to antigen-coated
wells, where they were diluted 1:10. After incubation
and washing, monoclonal γ-chain specific anti-human
IgG conjugated with β-galactosidase was added. Develop-
ment solution (0.01 % 4-methylumbelliferyl-β-D-galacto-
side) was then applied, and the reaction subsequently
terminated by adding 4 % sodium carbonate. An autoanti-
body concentration ≥16 IU/ml was considered positive
Table 1 Characteristics of the SLE patients (n = 188) in relation to the presence of anti-HMGB1
Mean (range) or % P valuea
All patients n = 188 Anti-HMGB1 positive n = 43 Anti-HMGB1 negative n = 145
Age, years 49.1 (18–88) 44.9 (19–80) 50.4 (18–88) ns
Females 88.8 % 88.4 % 89.0 % ns
Disease duration, years 10.9 (0–45) 10.9 (0–39) 10.9 (0–45) ns
Prednisolone dosage, mg/day 5.1 (0–60) 8.3 (0–60) 4.2 (0–25) ns
SLICC/ACR damage index, score 1.1 (0–8) 1.2 (0–8) 1.1 (0–8) ns
SLEDAI-2K, score 2.5 (0–24) 3.1 (0–24) 2.3 (0–16) ns
PGA, score 0.4 (0–4) 0.6 (0–4) 0.4 (0–3) ns
Patients meeting SLICC-12, n (%) 183 (97.3) 42 (97.7) 141 (97.2) ns
Fulfilled ACR-82 criteria, n 4.8 (3–9) 5.0 (3–9) 4.7 (3–8) ns
ACR-82 criteria, n (%)
1. Malar rash 87 (46.3) 20 (46.5) 67 (46.2) ns
2. Discoid rash 32 (17) 7 (16.3) 25 (17.2) ns
3. Photosensitivity 103 (54.8) 23 (53.5) 80 (55.2) ns
4. Oral ulcers 21 (11.2) 6 (14) 15 (10.3) ns
5. Arthritis 144 (76.6) 35 (81.4) 109 (75.2) ns
6. Serositis 72 (38.3) 19 (44.2) 53 (36.6) ns
7. Renal disorder 43 (22.9) 10 (23.3) 33 (22.8) ns
8. Neurologic disorder 11 (5.9) 3 (7) 8 (5.5) ns
9. Hematologic disorder 106 (56.4) 20 (46.5) 86 (59.3) ns
10. Immunologic disorder 92 (48.9) 29 (67.4) 63 (43.4) 0.009
11. IF-ANA 185 (98.4) 42 (97.7) 143 (98.6) ns
aMann–Whitney U test and Chi2 test, respectively. HMGB1 high mobility group box protein-1, SLEDAI-2K systemic lupus erythematosus disease activity index 2000,
SLICC Systemic Lupus International Collaborating Clinics, ACR American College of Rheumatology, PGA physician’s global assessment, IF-ANA immunofluorescence
antinuclear antibodies, ns not significant
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according to the manufacturer’s suggestion. Samples
above the assay range (≥379 IU/ml) were given a value of
450 IU/mL in statistical analyses.
Other laboratory analyses
At all patient visits, routine laboratory analyses were
performed at Linköping University Hospital, apart from
classical complement function in fresh frozen plasma sam-
ples, which was analyzed at Uppsala University Hospital.
Ethics
Oral and written informed consent was obtained from
all SLE subjects. The study protocol was approved by
the Regional Ethics Review Board in Linköping (Dnr:
M75-08/2008). The Regional Ethics Review Board in
Stockholm approved the part of the study involving
control subjects.
Statistical analyses
The Mann–Whitney U test was used to evaluate differ-
ences in anti-HMGB1 levels between patients and
controls. In order to distinguish differences in anti-
HMGB1 levels between ANA-groups, Kruskal–Wallis
with Dunn’s multiple comparison post-hoc test was
used. Spearman’s correlation was used to determine the
association between anti-HMGB1 and disease variables.
Two-tailed P values <0.05 were considered significant.
Statistical analyses were performed with SPSS Statistics
22 (IBM, Armonk, NY, USA) or GraphPad Prism 5,
version 5.04 (GraphPad Software, La Jolla, CA, USA).
Results
IF-ANA and anti-HMGB1 antibodies
At inclusion, 23 % of the SLE patients were anti-HMGB1
antibody-positive compared to 5 % of the controls (Fig. 1a).
The average level of anti-HMGB1 antibodies was signifi-
cantly higher (P <0.0001) among the SLE patients (median
132.5 AU) compared to the healthy controls (median
81 AU) (Fig. 1a). To evaluate the importance of anti-
HMGB1 antibodies in renal SLE, we compared anti-
HMGB1 antibody levels in patients meeting the ACR-82
classification criterion for renal disorder and patients who
did not fulfil this criterion. Furthermore, patients were
categorized by disease activity in the renal domain (i.e.,
presence of urinary casts, hematuria, proteinuria and
leukocyturia), and into active (SLEDAI-2K >4) and non-
active (SLEDAI-2K ≤4). No significant differences were
found between the groups (Fig. 1b).
Levels of anti-HMGB1 antibodies were also analyzed
in the consecutive serum samples from 18 patients: 11
(61 %) of these tested positive on at least one occasion.
Anti-HMGB1 levels were compared at the highest and
lowest disease activity (defined by SLEDAI-2K), but no
significant differences were found (Additional file 1). See
Additional file 2 for longitudinal data on each of the 11 in-
dividuals who were ever anti-HMGB1-positive.
As shown in Table 1, 98.4 % of the 188 SLE patients
included in this study had ever been IF-ANA-positive,
97.7 % among anti-HMGB1-positive patients and 98.6 %
among anti-HMGB1-negative patients. On further
comparison of anti-HMGB1-positive and anti-HMGB1-
negative SLE patients there were no differences in
baseline data on age, sex, disease duration, prednisolone
medication, disease activity, or disease phenotype based
on the ACR-82 classification criteria (Table 1).
The present serologic point prevalence results, however,
revealed that only 124 (66 %) of the SLE cases were IF-
ANA-positive. Among the ANA-positive patients, 74 % of
the sera produced a homogenous (chromosomal) IF-ANA
Fig. 1 Serum anti-high mobility box protein-1 (HMGB1) antibody
levels determined by ELISA. a The average level of anti-HMGB1 was
significantly higher in the systemic lupus erythematosus (SLE) patients
(median 132.5 arbitrary units (AU)) compared to the healthy controls
(median 81 AU). Dashed line indicates the cut-off level for a positive
test. Solid lines represent median values. Note the axis break. b Serum
levels in SLE patients categorised into renal non-active, renal active
(see text for definitions), non-renal active with systemic lupus
erythematosus disease activity index (SLEDAI)-2K ≤4, and non-renal
active with SLEDAI-2K >4
Wirestam et al. Arthritis Research & Therapy  (2015) 17:338 Page 5 of 10
staining pattern (with or without other patterns), and
26 % thus had other (extra-chromosomal) IF-ANA
staining patterns. The IF-ANA-positive patients with
a homogenous nuclear staining pattern had significantly
(P = 0.004) higher levels of anti-HMGB1 antibodies (me-
dian 180 AU) compared to the IF-ANA-negative group
(median 83 AU), whereas the ANA-positive patients with
other nuclear (non-homogenous) staining patterns did not
differ in anti-HMGB1 status from the ANA-positive
patient group (Fig. 2).
Anti-HMGB1 antibodies versus disease activity measures
Levels of anti-HMGB1 antibodies correlated positively
with anti-dsDNA antibody levels as analyzed by EliA™
(r = 0.49; P <0.001). Less pronounced correlations were
found regarding disease activity (SLEDAI-2K; r = 0.15;
P = 0.04), classical complement function (r = –0.24; P =
0.002) and plasma levels of C4 (r = –0.23; P = 0.002). There
was no significant association with disease phenotypes
(Table 1) or organ damage (SLICC/ACR damage index).
Anti-HMGB1-positive patients with IF-ANA reactivity to
chromatin-associated antigens
As illustrated in Fig. 3a, among the 43 SLE patients testing
positive for anti-HMGB1 antibodies, 7 (16 %) also had
anti-dsDNA antibodies analyzed by the line blot assay, 2
(4.7 %) had anti-nucleosome Nu2 antibodies (line blot),
and 2 (4.7 %) had anti-histone reactivity (line blot): 12 of
the 43 anti-HMGB1-positive patients (28 %) had antibodies
reactive to dsDNA and to nucleosome Nu2 and histones.
In contrast to the anti-HMGB1-positive patients, only
3.4 % of the anti-HMGB1-negative SLE patients were
triple-positive for antibodies against dsDNA, Nu2, and
histones, while 66 % were negative for all of these ANA
specificities (Fig. 3b).
Cellular localization of HMGB1
We could neither identify HMGB1 in nuclei of non-
dividing HEp-2 cells, nor in the chromatin of dividing
cells. Instead, a diffuse cytoplasmic staining was seen here,
but not in the control slides incubated with detection anti-
body alone (Fig. 4a–b). However, in unfixed rat liver cryo-
stat sections a faint IF-ANA reaction with a homogenous
nuclear staining pattern was observed in the hepatocytes
indicating nuclear localization of HMGB1 (Fig. 4c).
Discussion
Anti-HMGB1 antibodies have previously been reported
in SLE patients [26, 31, 32] and there are also a few
reports on elevated HMGB1 levels in SLE [24–26, 40].
However, the clinical value and possible role of anti-
HMGB1 antibodies in the pathogenesis of SLE remains
elusive and further studies on this matter are warranted.
Apart from SLE, the presence of anti-HMGB1 antibodies
has been reported in other chronic inflammatory diseases
[29, 30, 41–43]. The present study was undertaken to de-
termine the levels of anti-HMGB1 antibodies in sera from
SLE patients in relation to other disease variables.
By utilizing a novel ELISA, we confirmed that anti-
HMGB1 antibodies are significantly increased in SLE as
compared to healthy controls. Among the 188 SLE pa-
tients included in the present study, we found that IgG
anti-HMGB1 antibodies were present in about 1/4 of the
cases. Circulating levels of anti-HMGB1 antibodies had
a fair degree of correlation with anti-dsDNA antibody
levels and less pronounced, but statistically significant,
correlation with disease activity markers such as classical
complement activation, reduced levels of complement
protein C4 and with disease activity index SLEDAI-2K.
However, we did not observe any significant correlation
between fluctuations of anti-HMGB1 levels and SLE
disease activity in the 18 patients for whom we had
prospective data (see Additional file 2). The association
between anti-HMGB1 antibodies and renal involvement
was not as obvious in the present study compared to the
observation by Abdulahad et al. [26]. The reason for this
discrepancy may be due to both differences in study
population (ethnicity, SLE phenotypes and disease activity)
and in methodology. The amino acid sequence of the
recombinant HMGB1 used in this study originates from
Fig. 2 Indirect immunofluorescence (IF) microscopy for antinuclear
antibodies (ANA) and anti-high mobility box protein-1 (HMGB1)
antibodies. Serum levels determined by ELISA of anti-HMGB1 among
systemic lupus erythematosus patients grouped according to
immunofluorescence patterns of ANA. There were 34 % ANA-
negative and 66 % ANA-positive patients. IF-ANA-positive patients
with a homogenous nuclear staining pattern had significantly higher
levels of anti-HMGB1 antibodies compared to the IF-ANA negative
group. Dashed line indicates cut-off level for a positive anti-HMGB1
test; solid lines represent median anti-HMGB1 levels. Note the axis
break. AU arbitrary units
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rat. The sequence homology between rat and human
HMGB1 is 99 % and the differences lie within the highly
acidic C-terminal tail. Aspartic acids and glutamic acids
have been interchanged in three positions, however
no functional differences nor any impact on antibody
epitopes have been reported in the literature [31].
A positive IF-ANA test is a hallmark of SLE [44].
HMGB1 is a non-histone nucleosomal protein (although
it can shuttle to the cytoplasm and become released
extracellularly). Therefore, it is not farfetched to assume
that anti-HMGB1 antibodies should give rise to a
homogenous ANA staining pattern in conventional
IF-ANA tests on HEp-2 cells, i.e., the predominating
clinical IF-ANA test worldwide. Indeed, we found that
a positive anti-HMGB1 antibody test by ELISA was
predominantly associated with a homogenous IF-ANA
Fig. 3 Antinuclear antibodies (ANA) specificity in anti-high mobility box protein-1 (HMGB1)-positive patients. Overlap of ANA specificity in anti-HMGB1
antibody-positive systemic lupus erythematosus (SLE) patients (a) and anti-HMGB1 antibody-negative SLE patients (b), measured with a line blot
technique detecting anti-dsDNA, anti-histone and anti-nucleosome antibodies
Fig. 4 Cellular localization of high mobility box protein-1 (HMGB1). Indirect immunofluorescence microscopy images. a Cytoplasmic/extra-chromosomal
HEp-2 cell immunofluorescence after incubation with rabbit IgG anti-HMGB1 followed by FITC-conjugated anti-rabbit IgG. b Negative control HEp-2 cells
incubated with fluorescein-isothiocyanate (FITC)-conjugated anti-rabbit IgG alone. c Hepatocyte nuclear fluorescence after incubation of rat liver cryostat
section with rabbit anti-HMGB1 and FITC anti-rabbit IgG
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(with or without other ANA patterns). Surprisingly,
however, we found that incubation with polyclonal
rabbit anti-HMGB1 antibodies did not generate nuclear
staining on HEp-2 cells, but rather a diffuse cytoplasmic
staining pattern. As the HEp-2 cells are derived from a hu-
man adenocarcinoma, and as the location of HMGB1 may
predominate in the cytoplasm of malignant cells [45, 46],
this could be a plausible explanation for the cytoplasmic
staining of HMGB1 in HEp-2 cells. Another possible ex-
planation for the cytoplasmic location of HMGB1 could
be a fixation artifact with redistribution of nuclear
HMGB1 to the cytoplasm. The importance of fixatives has
been highlighted previously, e.g., as regards distribution of
cellular (membrane-bound, cytoplasmic, nuclear) antigens
[47–49], including HMGB1 [30]. Whatever the reason for
divergent staining patterns yielded by anti-HMGB1
antibodies when applied to fixed HEp-2 cells, as com-
pared to unfixed rat liver sections, it is highly unlikely
that serum anti-HMGB1 antibodies will be identified
as typical positive IF-ANA when the commercially
available HEp-2 cell substrates are used in clinical la-
boratory routine setups for IF-ANA diagnostics. The
seemingly low point prevalence (66 %) of IF-ANA-
positive patients in our cohort of prevalent cases may
appear bothering, but is well in line with what we
and others have shown applying a cut-off level for
positive IF-ANA ≥95th percentile among healthy fe-
male controls [4–6, 50].
The possible biological roles of anti-HMGB1 antibodies
have been considered in relation to other inflammatory
disorders. For instance, the presence of autoantibodies to
HMGB1 in sepsis has been shown to be associated with
increased survival among critically ill patients, thus
indicating that the induction of autoantibodies can be
beneficial in infectious diseases [51]. Studies in animal
models of arthritis and lupus have shown that treatment
with anti-HMGB1 antibodies can strikingly attenuate
disease by blocking the pro-inflammatory function of
HMGB1 [52–54]. Administration of a neutralising mono-
clonal anti-HMGB1 antibody to the lupus-prone BXSB
mice attenuates proteinuria, glomerulonephritis, circulat-
ing anti-dsDNA, immune complex deposition and levels
of cytokines in serum [53].
HMGB1 that is passively released during secondary ne-
crosis is not cytokine-inducing due to irreversible
oxidation of the three cysteines that are required for
HMGB1 function as a cytokine inducer [20]. Actively se-
creted HMGB1 is acetylated, in contrast to the passively
released HMGB1 [55]. In order to fully elucidate the role
of HMGB1 (and anti-HMGB1 antibodies) in SLE, the
molecular isoform of HMGB1 (and antibody fine-
specificities) must be determined. However, analyzing the
isoform of extracellular HMGB1 can today only be
measured by analytical tandem mass spectrometry [56],
which is a time-consuming approach not applicable for
studying large patient cohorts and was beyond the scope
of the present study. To study molecular isoforms could
potentially identify the source of extracellular HMGB1
that will further clarify the role of HMGB1 in SLE and also
the generation of anti-HMGB1 antibodies.
Although anti-HMGB1 antibodies occur in patients
with different inflammatory disorders, it does not neces-
sarily imply, nor exclude, that they are pathogenic. Based
on the therapeutic studies described above, anti-HMGB1
autoantibodies may hypothetically even be beneficial in
some instances. Obviously, the question of whether
anti-HMGB1 antibodies have protective/neutralising
or pathogenic roles in SLE needs further investigations.
Conclusion
We confirm that anti-HMGB1 antibodies occur in SLE
and correlate with disease activity variables. Although
anti-HMGB1 antibodies measured by ELISA often coin-
cide with nuclear staining, our results indicate that anti-
HMGB1 antibodies do not give rise to nuclear staining of
the widely used HEp-2 cell IF-ANA microscopy slides.
Additional files
Additional file 1: Figure shows anti-high mobility group box
protein-1 (HMGB1) antibody levels at highest and lowest disease
activity. Highest and lowest disease activity was defined by peak systemic
lupus erythematosus disease activity index (SLEDAI)-2K score and remission
in the 18 patients selected for consecutive analysis. Dashed line indicates
cut-off level for positive test. (TIF 150 kb)
Additional file 2: Figure shows individual SLE manifestations and
longitudinal variations of anti-high mobility group box protein-1
(HMGB1), anti-dsDNA, classical complement function and systemic
lupus erythematosus disease activity index (SLEDAI)-2K. The graphs
illustrate individual variations in anti-HMGB1 (cut-off ≥300 U/ml), anti-dsDNA
(EliA; cut-off ≥16 IU/ml), classical complement function (reference interval
80 - 120 %) and SLEDAI-2K levels over time for the 11 individuals who were
ever anti-HMGB1 positive (B-L), who were followed consecutively. The first
graph (A) is an example graph describing titles and lines of the other graphs.
Observe that axes and scales are different in the graphs. (TIF 1063 kb)
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